What does Symbiox Investme do?

Symbiox Investment & Trading Co Ltd is a Non Banking Financial Company focused on trading in investments and textiles, with a market cap of Rs 11 Cr and recent net sales of 1 Cr. The company has a P/E ratio of 11.00 and reported no net profit for the latest quarter ending March 2025.

Overview: <BR>Symbiox Investment & Trading Co Ltd operates in the Non Banking Financial Company (NBFC) sector, focusing on trading in investments and textiles.<BR><BR>History: <BR>The company was incorporated in May 1979. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 11 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 11.00 <BR>Industry P/E: 23 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 0.63% <BR>Price to Book: 0.36<BR><BR>Contact Details: <BR>Address: 7A Rani Rashmoni Road, Kolkata West Bengal: 700013 <BR>Tel: 91-33-32515833 <BR>Email: symbioxinvestment100@gmail.com <BR>Website: http://www.symbioxinvestment.org

Has Symbiox Investme declared dividend?

No Dividend History Available

Who are the peers of the Symbiox Investme?

Symbiox Investme's peers include Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Libord Securitie, Nexus Surgical, Prism Medico, and BCL Enterprises. Symbiox Investme has below average management risk and capital structure, with a 1-year return of 25.00%.

Peers: The peers of Symbiox Investme are Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Libord Securitie, Nexus Surgical, Prism Medico, and BCL Enterprises.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bajaj Finance, Cholaman.Inv.&Fn, Muthoot Finance, and the rest. Average management risk is found at Jio Financial, Nexus Surgical, BCL Enterprises, and the rest. Good management risk is noted at Shriram Finance, while below average management risk is present at Symbiox Investme and Prism Medico. Growth is excellent at Jio Financial, while good growth is seen at Bajaj Finance, Cholaman.Inv.&Fn, and BCL Enterprises. Average growth is noted at Symbiox Investme, Shriram Finance, Nexus Surgical, and the rest, while below average growth is present at Prism Medico. Excellent capital structure is observed at Bajaj Finance, Jio Financial, Shriram Finance, Muthoot Finance, Nexus Surgical, and BCL Enterprises, while good capital structure is noted at Cholaman.Inv.&Fn, and below average capital structure is present at Symbiox Investme and Prism Medico.<BR><BR>Return Snapshot: Bajaj Finance has the highest 1-year return at 30.45%, while Jio Financial has the lowest at -20.18%. Symbiox Investme's 1-year return is 25.00%, which is significantly higher than Jio Financial's but lower than Bajaj Finance's. Additionally, Libord Securitie and Prism Medico have negative six-month returns.

What is the technical trend for Symbiox Investme?

As of June 4, 2025, Symbiox Investme's technical trend is neutral with mixed signals, showing a sideways movement influenced by mildly bullish weekly MACD, bearish monthly MACD, bullish Bollinger Bands, and conflicting KST momentum.

As of 4 June 2025, the technical trend for Symbiox Investme has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating some short-term strength but overall uncertainty. The Bollinger Bands are bullish on both weekly and monthly time frames, suggesting potential upward movement. However, daily moving averages are mildly bearish, which adds to the mixed outlook. The KST shows bearish momentum on the weekly but bullish on the monthly, further contributing to the indecisive trend. Overall, the technical indicators reflect a sideways movement with no strong bullish or bearish bias at this time.

Who are in the management team of Symbiox Investme?

As of March 2022, the management team of Symbiox Investme includes Mina Devi Agarwal, Samit Ray, Mahavir Verma, Bappa Mitra, Rajkumari Naskar, Nitesh Poddar, and Khushboo Pitti, who serve in various executive and independent director roles.

As of March 2022, the management team of Symbiox Investme includes the following individuals:<BR><BR>1. Mina Devi Agarwal - Independent Director<BR>2. Samit Ray - Executive Director<BR>3. Mahavir Verma - Executive Director<BR>4. Bappa Mitra - Independent Director<BR>5. Rajkumari Naskar - Additional Independent Director<BR>6. Nitesh Poddar - Independent Director<BR>7. Khushboo Pitti - Company Secretary & Compliance Officer<BR><BR>These members play various roles within the company's governance and management structure.

Who are the top shareholders of the Symbiox Investme?

The top shareholders of Symbiox Investme include Tyro Commercial Private Limited with 3.2%, Logihaze Solutions Private Limited at 2.47%, and individual investors holding 82.07%. There are no institutional holdings or pledged promoter shares.

The top shareholders of Symbiox Investme include Tyro Commercial Private Limited, which holds the highest promoter stake at 3.2%. The highest public shareholder is Logihaze Solutions Private Limited, with a holding of 2.47%. Additionally, individual investors collectively own a significant 82.07% of the company. There are no institutional holdings or pledged promoter shares reported.

How big is Symbiox Investme?

As of 24th July, Symbiox Investment & Trading Co Ltd has a market capitalization of 8.00 Cr, with Net Sales of 1.04 Cr and a Net Profit of 0.03 Cr for the latest four quarters. The balance sheet as of March 2024 shows Shareholder's Funds of 31.53 Cr and Total Assets of 31.84 Cr.

As of 24th July, Symbiox Investment & Trading Co Ltd has a market capitalization of 8.00 Cr, classifying it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 1.04 Cr and a Net Profit of 0.03 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 31.53 Cr and Total Assets of 31.84 Cr.

Are Symbiox Investme latest results good or bad?

Symbiox Investment & Trading Co. reported mixed results, with a significant decline in net sales of -63.20% but a notable increase in standalone net profit of 123.33%. While profitability shows improvement, the sharp drop in sales raises concerns, leading to a 'Strong Sell' rating from MarketsMOJO.

The latest results for Symbiox Investment & Trading Co. indicate a mixed performance. On one hand, the company experienced a significant decline in net sales, with a QoQ growth of -63.20%, which is a concerning trend compared to the previous quarter's growth of 177.78%. However, there is a positive aspect in terms of standalone net profit, which saw a remarkable increase of 123.33%, recovering from a negative growth of -287.50% in the prior quarter.<BR><BR>Overall, while the improvement in net profit is a positive sign, the sharp drop in net sales raises concerns about the company's revenue generation. Additionally, the financial scoring has improved from -2 to 0, suggesting some stabilization in financial metrics. However, the market sentiment remains negative, as reflected in the 'Strong Sell' rating from MarketsMOJO.<BR><BR>In summary, the results can be seen as flat overall, with some positive signs in profitability but significant challenges in sales performance.

When is the next results date for Symbiox Investme?

Symbiox Investme will declare its results on 12 November 2025.

Symbiox Investme is scheduled to declare its results on 12 November 2025.

How has been the historical performance of Symbiox Investme?

Symbiox Investme's historical performance from March 2014 to March 2015 showed increased net sales and operating income, but profitability declined, resulting in a loss after tax and reduced margins. Despite improved cash flow and asset growth, the company faced challenges in maintaining profitability.

Answer:<BR>The historical performance of Symbiox Investme shows a mixed trend over the years, particularly between March 2014 and March 2015.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2015, Symbiox Investme reported net sales of 1.46 Cr, a significant increase from 0.28 Cr in March 2014. The total operating income also rose to 1.46 Cr from 0.28 Cr, reflecting improved business activity. However, total expenditure increased to 1.44 Cr from 0.27 Cr, leading to an operating profit (PBDIT) of 0.02 Cr, slightly up from 0.01 Cr in the previous year. Despite this, the profit before tax remained low at 0.02 Cr, compared to 0.01 Cr in March 2014. The company faced a loss in profit after tax, reporting -0.09 Cr in March 2015, down from a profit of 0.01 Cr in the prior year. The earnings per share (EPS) also declined to -0.03 from 0.01. The operating profit margin decreased to 1.58% from 4.23%, while the profit after tax margin fell to -6.11% from 5.28%. On the balance sheet, total assets were reported at 31.97 Cr in March 2025, showing a slight increase from 31.84 Cr in March 2024. The company maintained no long-term borrowings and reported a book value per share of 10.14 in March 2025, up from 10.08 in March 2024. Cash flow from operating activities improved to 3.00 Cr in March 2025, reversing a negative trend from the previous year. Overall, while there were increases in sales and operating income, the company struggled with profitability and margins during this period.

Should I buy, sell or hold Symbiox Investme?

Is Symbiox Investme overvalued or undervalued?

As of December 3, 2025, Symbiox Investme is considered risky and overvalued with a PE ratio of -832.24, significantly underperforming its peers and the Sensex, which reflects a lack of investor confidence.

As of 3 December 2025, the valuation grade for Symbiox Investme has moved from very expensive to risky, indicating a significant shift in perception. The company is currently deemed overvalued, with a staggering PE ratio of -832.24, an EV to EBIT of 5.81, and a price to book value of 0.26. These figures suggest that the market is pricing the stock unfavorably compared to its earnings potential and asset value.<BR><BR>In comparison to its peers, Symbiox Investme's valuation metrics are considerably worse. For instance, Bajaj Finance has a PE ratio of 34.68 and an EV to EBITDA of 19.55, while Life Insurance boasts a PE of 10.75 and an EV to EBITDA of 8.83. The stark contrast in these ratios highlights the challenges Symbiox faces in attracting investor confidence. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -50.92% compared to the Sensex's 8.92%, further reinforcing the notion of overvaluation.

Which are the latest news on Symbiox Investme?

Why is Symbiox Investme falling/rising?

As of 04-Dec, the stock price of Symbiox Investment & Trading Co Ltd is currently at 2.79, reflecting a 4.89% increase today, driven by heightened investor participation. However, it has a year-to-date decline of 48.52% and is trading below its moving averages, indicating a longer-term downward trend.

As of 04-Dec, the stock price of Symbiox Investment & Trading Co Ltd is rising, currently at 2.79 with a change of 0.13, representing an increase of 4.89%. This rise is notable as it outperformed the sector by 4.77% today. Additionally, there has been a significant increase in investor participation, with a delivery volume of 11.02k on December 3, which has risen by 79.24% compared to the 5-day average. <BR><BR>However, it is important to note that despite today's positive movement, the stock has been underperforming over longer periods, with a year-to-date decline of 48.52% and a 3-year decline of 61.36%. The stock is currently trading below its moving averages across various time frames, indicating a longer-term downward trend. Nonetheless, the current day's performance suggests a temporary rebound in the stock price, driven by increased trading activity and investor interest.